MXPA04004035A - Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos. - Google Patents

Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos.

Info

Publication number
MXPA04004035A
MXPA04004035A MXPA04004035A MXPA04004035A MXPA04004035A MX PA04004035 A MXPA04004035 A MX PA04004035A MX PA04004035 A MXPA04004035 A MX PA04004035A MX PA04004035 A MXPA04004035 A MX PA04004035A MX PA04004035 A MXPA04004035 A MX PA04004035A
Authority
MX
Mexico
Prior art keywords
controlled
dosage form
agent
release
form according
Prior art date
Application number
MXPA04004035A
Other languages
English (en)
Spanish (es)
Inventor
Laure Patricia Ouadji Njiki
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc filed Critical Labopharm Inc
Publication of MXPA04004035A publication Critical patent/MXPA04004035A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MXPA04004035A 2001-10-29 2002-10-29 Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos. MXPA04004035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01125761 2001-10-29
PCT/EP2002/012062 WO2003037296A2 (fr) 2001-10-29 2002-10-29 Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques

Publications (1)

Publication Number Publication Date
MXPA04004035A true MXPA04004035A (es) 2004-10-29

Family

ID=8179102

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004035A MXPA04004035A (es) 2001-10-29 2002-10-29 Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos.

Country Status (6)

Country Link
EP (1) EP1439820A2 (fr)
JP (1) JP2005509643A (fr)
AU (1) AU2002351798A1 (fr)
CA (1) CA2466032A1 (fr)
MX (1) MXPA04004035A (fr)
WO (1) WO2003037296A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
JP5355002B2 (ja) * 2008-09-10 2013-11-27 オリンパスメディカルシステムズ株式会社 浮き量合否判定システム、浮き量合否判定用表示システム、浮き量合否判定方法および浮き量合否判定用表示方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
PL346798A1 (en) * 1998-09-14 2002-02-25 Ranbaxy Lab Ltd Orally administered controlled drug delivery system providing temporal and spatial control
AP2002002410A0 (en) * 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
WO2001058424A1 (fr) * 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Composition flottante de liberation de medicament

Also Published As

Publication number Publication date
CA2466032A1 (fr) 2003-05-08
JP2005509643A (ja) 2005-04-14
EP1439820A2 (fr) 2004-07-28
WO2003037296A3 (fr) 2003-12-24
WO2003037296A2 (fr) 2003-05-08
AU2002351798A1 (en) 2003-05-12

Similar Documents

Publication Publication Date Title
Singh et al. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention
AU774957B2 (en) Hydrodynamically balancing oral drug delivery system
Kotreka et al. Gastroretentive floating drug-delivery systems: a critical review
JP4088420B2 (ja) 多糖類を利用した大腸選択性薬物伝達組成物および医薬製剤
AU628754B2 (en) Therapeutic agents
US7674480B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20060099245A1 (en) Hydrodynamically balancing oral drug delivery system with biphasic release
KR101643626B1 (ko) 결장 흡수용 페닐에프린 약제학적 제형 및 조성물
RU2325163C2 (ru) Композиции с пролонгированным высвобождением, включающие ламотригин
EA012377B1 (ru) Твёрдые пероральные фармацевтические композиции для введения один раз в сутки, содержащие прегабалин, матрицеобразующий агент и агент набухания
CN113476421B (zh) 一种非布司他的控释组合物及其制备方法
US20020119192A1 (en) Controlled release formulations for oral administration
EP1513504A1 (fr) Formes posologiques orales a liberation prolongee de gabapentine
KR101648490B1 (ko) 위체류 약물 전달시스템을 이용한 서방성 경구용 제제
WO2005007074A2 (fr) Formes dosifiees a liberation controlee a base de gomme gellane a administrer par voie orale, une nouvelle technologie pour la retention gastrique
ES2202858T3 (es) Formas de dosificacion de sertralina de liberacion retardada.
MXPA04004035A (es) Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos.
Bhoyar et al. An overview of a gastro retentive floating drug delivery system
US20030138486A1 (en) Methods and dosage forms for improving the bioavailability of therapeutic agents
Kumar et al. A systematic review on floating drug delivery system
WO2002102415A1 (fr) Systeme flottant gastrique
Mercy et al. FORMULATION AND EVALUATION OF GASTRORETENTIVE FLOATING IN-SITU GEL OF MINOCYCLINE HCL
TWI229609B (en) Pharmaceutical composition of orally administered controlled drug delivery system providing temporal and spatial control
CN1582903A (zh) 酶降解依赖型结肠定位释药柱塞胶囊及其制备方法
Tutunji Development of a gastroretentive controlled release metformin delivery system